SAB Biotherapeutics, Inc. (SABSW) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 3 Buy.
Analysts estimate Earnings Per Share (EPS) of $-3.68 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.68 vs est $-3.68 (beat +0%). 2025: actual $0.22 vs est $-0.41 (beat +153.4%). Analyst accuracy: 0%.
SABSW Analyst Ratings
Buy
Based on 3 analysts giving stock ratings to SAB Biotherapeutics, Inc. in the past 3 months
EPS Estimates — SABSW
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$3.68
vs Est –$3.68
▼ 0.0% off
2025
Actual $0.22
vs Est –$0.41
▲ 287.1% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — SABSW
100%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▼ 0.1% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
